Navigation Links
Dragon Pharma announces receipt of preliminary proxies to approve merger

VANCOUVER, July 7 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the "Company" TSX: DDD; OTCBB: DRUG) announced that based on the receipt of preliminary proxies, the Company believes that it has sufficient votes to approve the Agreement and Plan of Merger ("Merger") by and among Dragon, Chief Respect Limited, Datong Investment Inc., a subsidiary of Chief Respect Limited, and Mr. Yanlin Han. The Merger must be approved by holders of a majority of the outstanding shares of the Company's voting common stock and a majority of the votes cast by the minority shareholders of outstanding shares of the Company's voting common stock excluding the votes cast by Mr. Han. If the Merger is approved, Datong Investment Inc. will merge with and into Dragon and each holder of Dragon shares of common stock, excluding Mr. Han, will receive $0.82 per share.

The receipt of preliminary proxies is not an official vote. Accordingly, shareholders are encouraged to vote prior to or at the Special Meeting of Shareholders of the Company to be held on Tuesday, July 20, 2010 at 10:30 a.m., Pacific Time at the Company's corporate office located at Suite 310, 650 West Georgia Street, Vancouver, British Columbia, Canada V6B 4N9, at which time the Company expects to finalize shareholder approval of the proposed Merger.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including Clavulanic Acid, an API to combine with Amoxicillin to fight resistance, and 7-ACA, a key intermediate to produce cephalosporin antibiotics, and formulated cephalosporin antibiotic drugs. To learn more about Dragon Pharmaceutical Inc., please visit

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the meeting of Company's shareholders, and the closing of the merger, that involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from outcomes expressed or implied by this press release. Such risk factors include, among others, that shareholders who have submitted their proxies to approve the merger may subsequently change their vote and the matters submitted for shareholder approval at the meeting of Company's shareholders may not be approved. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in the Risk Factors sections of the definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on June 28, 2010, and from time to time in Company's other reports filed with the SEC.

Additional Information and Where to Find It

In connection with the proposed merger, on June 28, 2010, the Company filed with the SEC a Schedule 13E-3, and a definitive proxy statement for the meeting of stockholders of the Company to be convened to approve the merger. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, DRAGON'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Stockholders may obtain a free copy of the proxy statement, and other documents filed by us with the SEC, at the SEC's web site at Free copies of the proxy statement and our other filings with the SEC may also be obtained from us. Free copies of our filings may be obtained by directing a request to Dragon Pharmaceutical, Inc., 650 West Georgia Street, Suite 310, Vancouver, British Columbia, Canada V6B 4N9 Attention: Maggie Deng, Secretary. Copies of the proxy statement may also be obtained at our website,

SOURCE Dragon Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dragon to Present at BioContact Quebec 2008
2. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
3. Dragon Pharma Announces June 21, 2009 for 2009 Annual Shareholders Meeting
4. Dragon Pharma Announces Results of 2009 Annual General Meeting
5. Dragon Pharma reports 2010 first quarter financial results
6. Dragon Pharma announces date of special meeting
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
8. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
9. Par Pharmaceutical Reports Second Quarter 2008 Results
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... ALBANY, New York , November 24, 2015 /PRNewswire/ ... According to a recent market research report released by ... is projected to expand at a CAGR of 17.5% ... titled "Non-invasive Prenatal Testing Market - Global Industry Analysis, ... 2022", estimates the global non-invasive prenatal testing market to ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
Breaking Biology Technology:
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 /PRNewswire/ ... innovator in modern authentication and a founding member of ... of its latest version of the Nok Nok™ S3 ... use standards-based authentication that supports existing and emerging methods ... is ideal for organizations deploying customer-facing applications that require ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
(Date:10/22/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... ended September 30, 2015.  --> ... million, a decrease of 33% compared to $6.0 million in the ... 2015 was $2.2 million, or $0.10 per diluted share, which compared ... period a year ago.  --> ...
Breaking Biology News(10 mins):